UniProt Q15835 · PDB · AlphaFold · Substrate: Casein · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 86.1% | 13.9% | 78.64 | 0.500 |
| 2 | Repotrectinib | 71.1% | 28.9% | 84.21 | 0.608 |
| 3 | Lorlatinib | 62.3% | 37.7% | 97.24 | 0.694 |
| 4 | Upadacitinib | 38.9% | 61.1% | 97.98 | 0.663 |
| 5 | Darovasertib | 37.3% | 62.7% | 96.99 | 0.719 |
| 6 | Pirtobrutinib | 23.6% | 76.4% | 99.49 | 0.656 |
| 7 | Capivasertib | 21.3% | 78.8% | 96.48 | 0.644 |
| 8 | Baricitinib | 18.7% | 81.3% | 97.99 | 0.616 |
| 9 | Abemaciclib | 18.6% | 81.4% | 91.48 | 0.563 |
| 10 | Pexidartinib | 18.4% | 81.6% | 99.49 | 0.631 |
| 11 | Ruxolitinib | 17.3% | 82.7% | 98.25 | 0.592 |
| 12 | Quizartinib | 17.2% | 82.8% | 99.50 | 0.737 |
| 13 | Neratinib | 15.9% | 84.1% | 93.18 | 0.597 |
| 14 | Pralsetinib | 15.5% | 84.5% | 93.43 | 0.643 |
| 15 | Sunitinib | 15.1% | 84.9% | 91.73 | 0.524 |
| 16 | Canertinib | 14.3% | 85.7% | 96.49 | 0.671 |
| 17 | Alectinib | 14.2% | 85.8% | 95.49 | 0.651 |
| 18 | Pacritinib | 13.8% | 86.2% | 88.64 | 0.452 |
| 19 | Entrectinib | 13.7% | 86.3% | 93.69 | 0.671 |
| 20 | Ceritinib | 13.3% | 86.7% | 95.44 | 0.618 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.06
- Epithelial log2(TPM+1): 0.12
- Fold change: -0.07
- Status: No significant change
Selectivity landscape vs inhibition on GRK1
Each point is one of the 92 approved drugs; color = inhibition % on GRK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…